Phase Forward to Host Sixth Annual European Users Conference

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced it will host its sixth annual European Users Conference (EUC) on April 9-10 at the historic One Whitehall Place in Central London, U.K. The event will bring together customers in order to highlight industry trends as well as product implementation case studies and updates on the company’s electronic data capture (EDC) and drug safety solutions. The conference will commence on April 10 with a welcome address given by Phase Forward President and CEO Bob Weiler and Senior Vice President of Worldwide Sales Steve Powell. The conference industry keynote speaker will be Jonathan Lange, Partner, Global Lead, Clinical and Regulatory Services at Accenture, who will deliver a speech titled, "Industry Trends: Outsourcing and Offshoring.” The customer keynote speech titled, "A Personal Vision of the Future of Safety” will be presented by Dr. Val Simmons, European Qualified Person for Pharmacovigilance, Executive, Global Patient Safety at Eli Lilly and Company. In addition, Marina Nillni, Clinical Trials IS, Team Leader at Dana-Farber Cancer Institute, will present a speech titled, "Deploying InForm™ at the World's Largest Comprehensive Cancer Centre – How to Address the Challenges of Data Collection for Oncology Trials.” John Rosenblum, Vice President of Phase Forward’s LabPas Group, will also give a presentation called, "LabPas – Responding to the Needs of Phase I Clinics,” which will highlight Phase Forward’s LabPas product suite. A full day of sessions will follow, including two parallel tracks focusing on eClinical and safety. Presentations to be highlighted in the eClinical track include: "EDC Governance, Implementation and Process Re-design at Abbott,” by Detlef Nehrdich, Director Statistics and Data Management Europe and Global EDC Project Manager, Abbott GmbH & Co KG "Strategic Reasoning for EDC Use and Data Management Benefits to be Gained,” by Robert Ellison, EDC Implementation Manager, ICON "What Does Mature EDC Look Like? An Overview of Successful Scalability and Process Improvement,” by Selina Sibbald, Director, Global EDC, Quintiles "The GlaxoSmithKline Template for Using InForm in Phase I,” by Sam Garthside, Lead Data Scientist, Clinical Pharmacology Data Sciences, GlaxoSmithKline Presentations to be showcased in the safety track include: "The GSK CTSD Instream Project,” by Shaun Jones, Project Leader, Instream Workstream, GlaxoSmithKline "WebVDME and Signal Management Applications at AstraZeneca,” by Jenny Royle, Patient Safety Scientist, AstraZeneca "Our annual European event is a wonderful opportunity for our customers to collaborate on a shared vision – to leverage the power of next generation technologies in clinical trials,” said Bob Weiler, Phase Forward CEO and president. "As clinical trials continue to grow in complexity, we look forward to the opportunity to continue to work with and expand our customer base worldwide in order to provide technologies to ensure safer drugs are brought to market.” For additional event information and a more detailed agenda, visit: http://www.phaseforward.com/EUC_2008/default.aspx. About Phase Forward Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm™), phase I clinic automation (LabPas™), clinical data management (Clintrial™), clinical trials signal detection (CTSD™), strategic pharmacovigilance (WebVDME™ and Signal Management), adverse event reporting (Empirica™ Trace) and applied data standards (WebSDM™). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com. Cautionary Statement Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward’s products and services, the benefits to Phase Forward customers from the use of Phase Forward’s products and services, and expectations of continued used of Phase Forward’s products and services by customers. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward’s customers to realize benefits from the use of its products and services, changes in regulatory requirements applicable to Phase Forward’s customers and the manner in which they conduct business, the possibility that customers’ needs or plans may change over time, and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.